![]() |
Volumn 256, Issue 3, 2012, Pages
|
Which limits to the ALPPS approach?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
HEPATOIMINODIACETIC ACID TC 99M;
RADIOPHARMACEUTICAL AGENT;
UNCLASSIFIED DRUG;
ARTIFICIAL EMBOLISM;
ASSOCIATING LIVER PARTITION AND PORTAL VEIN LIGATION FOR STAGE HEPATECTOMY;
BILE DUCT CARCINOMA;
BILE DUCT FISTULA;
BILE DUCT LIGATION;
BILE DUCT OBSTRUCTION;
BILOMA;
CANCER CHEMOTHERAPY;
CANCER SURGERY;
CLINICAL ASSESSMENT;
COLORECTAL CANCER;
DISEASE ASSOCIATION;
GALLBLADDER CARCINOMA;
HUMAN;
LETTER;
LIVER;
LIVER ATROPHY;
LIVER FAILURE;
LIVER HYPERTROPHY;
LIVER METASTASIS;
LIVER REGENERATION;
LIVER RESECTION;
MULTIPLE CYCLE TREATMENT;
PANCREATICODUODENECTOMY;
POSTOPERATIVE PERIOD;
PRIMARY SCLEROSING CHOLANGITIS;
PRIORITY JOURNAL;
SURGICAL APPROACH;
SURGICAL PATIENT;
SURGICAL RISK;
VEIN LIGATION;
VOLUMETRY;
FEMALE;
HEPATECTOMY;
HUMANS;
LIVER NEOPLASMS;
MALE;
PORTAL VEIN;
|
EID: 84865448826
PISSN: 00034932
EISSN: 15281140
Source Type: Journal
DOI: 10.1097/SLA.0b013e318265fd64 Document Type: Letter |
Times cited : (87)
|
References (4)
|